These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 8198018

  • 1. Clinical implications of the biopharmaceutical properties of fluvastatin.
    Deslypere JP.
    Am J Cardiol; 1994 May 26; 73(14):12D-17D. PubMed ID: 8198018
    [Abstract] [Full Text] [Related]

  • 2. Development and pharmacology of fluvastatin.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan 26; 77A():11-5. PubMed ID: 8729584
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H, Fager G.
    Clin Pharmacokinet; 1997 May 26; 32(5):403-25. PubMed ID: 9160173
    [Abstract] [Full Text] [Related]

  • 6. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P, Kafonek S, Laurora I, Hunninghake D.
    Am J Cardiol; 1998 Mar 01; 81(5):582-7. PubMed ID: 9514454
    [Abstract] [Full Text] [Related]

  • 7. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
    Dujovne CA, Davidson MH.
    Am J Med; 1994 Jun 06; 96(6A):37S-40S. PubMed ID: 8017465
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Updated clinical safety experience with fluvastatin.
    Jokubaitis LA.
    Am J Cardiol; 1994 May 26; 73(14):18D-24D. PubMed ID: 8198019
    [Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I, Spinler SA, Johnson NE.
    Ann Pharmacother; 1995 May 26; 29(7-8):743-59. PubMed ID: 8520093
    [Abstract] [Full Text] [Related]

  • 11. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR.
    Am J Health Syst Pharm; 1995 Aug 01; 52(15):1639-45. PubMed ID: 7583826
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics of fluvastatin.
    Scripture CD, Pieper JA.
    Clin Pharmacokinet; 2001 Aug 01; 40(4):263-81. PubMed ID: 11368292
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A review of current clinical findings with fluvastatin.
    Garnett WR.
    Am J Cardiol; 1996 Sep 26; 78(6A):20-5. PubMed ID: 8875971
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
    Kong SX, Crawford SY, Gandhi SK, Seeger JD, Schumock GT, Lam NP, Stubbings J, Schoen MD.
    Clin Ther; 1997 Sep 26; 19(4):778-97. PubMed ID: 9377621
    [Abstract] [Full Text] [Related]

  • 16. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis A.
    Am J Cardiol; 1995 Jul 13; 76(2):62A-64A. PubMed ID: 7604801
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.
    Tse FL, Jaffe JM, Troendle A.
    J Clin Pharmacol; 1992 Jul 13; 32(7):630-8. PubMed ID: 1640002
    [Abstract] [Full Text] [Related]

  • 18. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
    Smit JW, Wijnne HJ, Schobben F, Sitsen A, de Bruin TW, Erkelens DW.
    Am J Cardiol; 1995 Jul 13; 76(2):89A-96A. PubMed ID: 7604808
    [Abstract] [Full Text] [Related]

  • 19. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP, Horsmans Y.
    Clin Pharmacokinet; 1996 Nov 13; 31(5):348-71. PubMed ID: 9118584
    [Abstract] [Full Text] [Related]

  • 20. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, Dallongeville J.
    Am J Cardiol; 1995 Jul 13; 76(2):65A-70A. PubMed ID: 7604802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.